EUC-001 is under clinical development by Eustralis Pharmaceuticals and currently in Phase II for Traumatic Brain Injury. According to GlobalData, Phase II drugs for Traumatic Brain Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EUC-001 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EUC-001 overview
EU-C-001 is under development for the control of intracranial pressure following traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE). It is administered through intravenous and oral route. EU-C-001 act by blocking Substance P which is a key mediator of inflammation due to immune complexes. Substance P activates inflammatory triggers throughout the body.
Eustralis Pharmaceuticals overview
Eustralis Pharmaceuticals (Eustralis), trading as PresSura Neuro, is a pharmaceutical and healthcare company The company offers treatment of therapeutics area in traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE) and post concussion syndrome (PCS) and others. It provides research and development of innovative life-saving therapies for acute injuries and life-threatening inflammatory responses. The company’s drug therapy provides a timely and effective restoration of normal blood flow and oxygen supply to the brain. It operates in Australia. Eustralis is headquartered in Melbourne, Victoria, Australia.
For a complete picture of EUC-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
